Author D. Imfeld, F. Pascucci
Journal Edition sofw journal 10-2020

Abstract

To address an identified consumer demand for skin care products that can create a natural-looking, lightly suntanned complexion all year round, DSM has been investigating safe means of stimulating skin pigmentation. Its novel pentapeptide Benzoyl Dipeptide-18 D-Phenylalanyl Arginyl D-Tryptophan Diproylamide Mesylate (trading under the name SYN-GLOW™) has been designed and synthesized to act as a melanocortin 1 receptor (MC1R) agonist. Its efficacy has been tested in ex-vivo and in-vivo studies which have demonstrated its potential to initiate and enhance skin pigmentation, with long-lasting results. The findings are presented here.

Back to top

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.